目的 探讨十味龙胆花颗粒联合布地奈德福莫特罗粉治疗支气管哮喘的临床疗效。方法 选择2018年1月-2019年1月在北京怀柔医院治疗的支气管哮喘患者82例，根据用药的差别分为对照组（41例）和治疗组（41例）。对照组给予布地奈德福莫特罗粉吸入剂，2吸/次，2次/d；治疗组在对照组的基础上口服十味龙胆花颗粒，3 g/次，3次/d。两组患者均治疗2周。观察两组患者临床疗效，同时比较治疗前后两组患者WHOQOL-BREF、LCQ、MARS-A和C-ACT评分，血清基质金属蛋白酶组织抑制剂-1（TIMP-1）、半胱氨酰白三烯（CysLTs）、降钙素原（PCT）、白细胞介素-4（IL-4）和白细胞介素-6（IL-6）水平，以及一秒用力呼气容积（FEV1）、用力肺活量（FVC）和最大呼气流量（PEF）水平。结果 治疗后，对照组临床有效率为80.49%，显著低于治疗组的97.56%，两组比较差异有统计学意义（P<0.05）。经治疗，两组患者LCQ、MARS-A、C-ACT和WHOQOL-BREF评分均明显升高（P<0.05），且治疗组患者这些评分明显高于对照组（P<0.05）。经治疗，两组患者血清TIMP-1、CysLTs、PCT、IL-4、IL-6水平均明显降低（P<0.05），且治疗组患者这些血清学指标水平明显低于对照组（P<0.05）。经治疗，两组患者FEV1、FVC、PEF水平均明显升高（P<0.05），且治疗组患者这些肺功能指标明显好于对照组（P<0.05）。结论 十味龙胆花颗粒联合布地奈德福莫特罗粉吸入剂治疗支气管哮喘可有效改善患者临床症状，促进肺功能改善，促进患者生活质量提高，具有一定的临床推广应用价值。

Objective To explore the clinical efficacy of Shiwei Longdanhua Granules combined with budesonide formoterol in treatment of bronchial asthma. Methods Patients (82 cases) with bronchial asthma in Beijing Huairou Hospital from January 2018 to January 2019 were divided into control (41 cases) and treatment (41 cases) groups based on different treatments. Patients in the control group were administered with Budesonide and Formoterol Fumarate Powder for inhalation, 2 inhalation/time, twice daily. Patients in the treatment group were po administered with Shiwei Longdanhua Granules on the basis of the control group, 3 g/time, three times daily. Patients in two groups were treated for 2 weeks. After treatment, the clinical efficacy was evaluated, and the WHOQOL-BREF, LCQ, MARS-A and C-ACT scores, the serum levels of TIMP-1, CysLTs, PCT, IL-4 and IL-6, and the FEV1, FVC, PEF levels in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control group was 80.49%, which was significantly lower than 97.56% in the treatment group, and there were differences between two groups (P<0.05). After treatment, the WHOQOL-BREF, LCQ, MARS-A, and C-ACT scores in two groups were significantly increased (P<0.05), and these scores in the treatment group were significantly higher than those in the control group (P<0.05). After treatment, the serum levels of TIMP-1, CysLTs, PCT, IL-4, and IL-6 in two groups were significantly decreased (P<0.05), and these serological indexes in the treatment group were significantly lower than those in the control group (P<0.05). After treatment, the FEV1, FVC and PEF levels in two groups were significantly increased (P<0.05), and these pulmonary function indexes in the treatment group were significantly better than those in the control group (P<0.05). Conclusion Shiwei Longdanhua Granules combined with budesonide formoterol in treatment of bronchial asthma can effectively improve the clinical symptoms, promote the improvement of lung function and the quality of life, which has a certain clinical application value.

R974